Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 8/20 | 0.53 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.53 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19040869 | 0.89 | GNAI3 (0.58) | GNAI3GNAO1GNAI1MEN1KMT2A | |
| SCHEMBL19032708 | 0.89 | GNAI3 (0.58) | GNAI3GNAO1GNAI1MEN1KMT2A | |
| SCHEMBL19032501 | 0.87 | GNAI3 (0.48) | GNAI3GNAO1GNAI1MEN1KMT2A | |
| SCHEMBL19040754 | 0.84 | GNAI3 (0.52) | GNAI3GNAO1GNAI1EPHX2MEN1 | |
| SCHEMBL20684331 | 0.83 | GNAI3 (0.52) | GNAI3GNAO1GNAI1MEN1KMT2A | |
| SCHEMBL23426287 | 0.83 | GNAI3 (0.51) | GNAI3GNAO1GNAI1EPHX2MEN1 | |
| SCHEMBL19040735 | 0.83 | GNAI3 (0.51) | GNAI3GNAO1GNAI1EPHX2MEN1 | |
| SCHEMBL19040739 | 0.83 | GNAI3 (0.51) | GNAI3GNAO1GNAI1EPHX2MEN1 | |
| SCHEMBL19032620 | 0.83 | GNAI3 (0.51) | GNAI3GNAO1GNAI1EPHX2MEN1 | |
| SCHEMBL20100813 | 0.82 | GNAI3 (0.50) | GNAI3GNAO1GNAI1EPHX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655402-A1 | NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV) | Providence Therapeutics Holdings Inc. (CA) | 2025-12-03 | — | — | EP | disclosed |
| EP-4452934-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | Providence Therapeutics Holdings Inc. (CA) | 2024-10-30 | — | — | EP | disclosed |
| WO-2024156053-A1 | NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV) | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2024-08-02 | — | — | WO | disclosed |
| EP-4402121-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023115221-A1 | IONIZABLE DILSULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023050003-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023044343-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |